Culture
Thursday Notes
Vertex will pay tens of millions to license a controversial CRISPR patent Vertex will pay tens of millions to license a controversial CRISPR patentThe company will pay rival Editas Medicine and the Broad Institute so that it can sell its breakthrough gene-editing treatment for sickle-cell disease.MIT Technology ReviewAntonio Regalado